Bausch Health Cos (NYSE:BHC) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Bausch Health Cos (NYSE:BHC) posted its earnings results on Wednesday. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.14), Zacks reports. Bausch Health Cos had a net margin of 3.61% and a negative return on equity of 9,620.34%.

Here are the key takeaways from Bausch Health Cos’ conference call:

• Bausch Health reported strong FY2025 operating results — an eleventh consecutive quarter of revenue and adjusted EBITDA growth, more than $1 billion in adjusted operating cash flow, and reduced net debt while improving its debt maturity profile through refinancing actions.
• The company announced a setback in R&D as the RED‑C Phase 3 trials failed to meet primary endpoints; management is reviewing the data to identify any alternative development opportunities.
• Solta completed the December 1, 2025 acquisition of Shibo in China to bring distribution in‑house, which management expects to drive long‑term, double‑digit growth for Solta and restore China as its largest geography.
• XIFAXAN, a key revenue driver, faces headwinds — Q4 included ~<$50M of one‑time Medicaid residuals and management warned of upcoming Medicare rebate and patent/generic risks (potential LOE/generic entry on Jan 1, 2028) that could materially pressure future EBITDA.
• 2026 guidance for Bausch Health (ex Bausch + Lomb) is modestly positive — revenue $5.25–$5.4B and adjusted EBITDA $2.0–$2.1B — while management says it will pursue targeted business development and consider monetizing its Bausch + Lomb stake to unlock shareholder value.

Bausch Health Cos Price Performance

NYSE BHC traded up $0.22 during trading hours on Wednesday, reaching $6.21. 2,779,723 shares of the stock traded hands, compared to its average volume of 2,155,968. The stock has a 50 day simple moving average of $6.67 and a two-hundred day simple moving average of $6.69. The company has a debt-to-equity ratio of 57.48, a current ratio of 1.30 and a quick ratio of 0.97. Bausch Health Cos has a 1 year low of $4.25 and a 1 year high of $8.69. The company has a market cap of $2.30 billion, a price-to-earnings ratio of 6.40 and a beta of 0.42.

Analysts Set New Price Targets

Several brokerages recently commented on BHC. Truist Financial lifted their target price on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Barclays initiated coverage on Bausch Health Cos in a research note on Monday, December 8th. They set an “equal weight” rating and a $8.00 price objective on the stock. Five analysts have rated the stock with a Hold rating, According to MarketBeat, Bausch Health Cos presently has an average rating of “Hold” and an average price target of $8.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paulson & CO. Inc. increased its holdings in shares of Bausch Health Cos by 3.5% during the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock worth $509,128,000 after buying an additional 2,500,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Bausch Health Cos by 65.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock worth $35,748,000 after acquiring an additional 2,038,813 shares during the period. MUFG Securities EMEA plc purchased a new position in shares of Bausch Health Cos during the 2nd quarter worth approximately $22,644,000. Dimensional Fund Advisors LP boosted its position in Bausch Health Cos by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,253,995 shares of the company’s stock worth $22,616,000 after purchasing an additional 241,546 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Bausch Health Cos by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,045,737 shares of the company’s stock valued at $14,223,000 after buying an additional 151,658 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.